免疫检查点抑制剂在头颈部鳞状细胞癌患者治疗中的研究进展

RESEARCH ADVANCES IN IMMUNE CHECKPOINT INHIBITORS IN TREATMENT OF HEAD AND NECK SQUAMOUS CELL CARCINOMA

头颈部鳞状细胞癌(head and neck squamous cell carcinoma,HNSCC)是一种高发病率的实体肿瘤,近年来传统的治疗手段如手术、化疗和放疗已经进入了瓶颈期,亟需新的治疗手段以改善患者预后。而免疫治疗是近几年新兴的肿瘤治疗手段,免疫检查点抑制剂(ICIs)在HNSCC及其他多种肿瘤的临床治疗中得到了广泛应用,并显示出良好的疗效。本文主要总结了ICIs在HNSCC治疗中的研究进展,及其与放疗和(或)化疗联合使用的效果,并对ICIs治疗产生的不良反应进行阐述,以探寻HNSCC患者免疫治疗的最优模式。

Head and neck squamous cell carcinoma(HNSCC)is a solid tumor with high morbidity.In recent years,traditional treatment methods,such as surgery,chemotherapy,and radiotherapy,are going through a bottleneck period,and therefore,new treatment methods are urgently needed to improve the prognosis of patients.Immunotherapy is an emerging treatment method for tumor in recent years,and immune checkpoint inhibitors(ICIs)have been widely used in the clinical treatment of HNSCC and other tumors with a marked clinical effect.This article summarizes the research advances in ICIs in the treatment of HNSCC and the effect of ICIs combined with radiotherapy and/or chemotherapy and elaborates on the adverse reactions of ICI the-rapy,in order to find the best paradigm of immunotherapy for HNSCC patients.